Navigation Links
Study of Patients on Chronic Opioid Therapy finds Likely Non-adherent Patients Have Increased Healthcare Costs, More Hospital Days
Date:3/17/2011

drug monitoring can provide clinicians with information to help improve medication adherence and outcomes among their patients, while controlling overall costs."

Among the Key Findings in the Study:

  • Overall healthcare spending for patients on chronic opioid therapy was over $23,000 per year (2008 dollars)
  • Total healthcare costs were 14 percent higher for likely non-adherent patients ($26,433) over a 12 month period following initial urine drug testing.
  • Likely non-adherent patients had 35 percent more hospital days.

  • About the Study: Data for the study were obtained from a managed care claims database of 18 million people enrolled between July 1, 2005 and Sept. 30, 2008. The data include geographically diverse commercial, Medicare Advantage and Medicaid health plan members in the United States. Data for classification were obtained from an independent database of urine drug testing results. Patients with evidence of long-term prescription opioid use (defined as at least 120 days over any consecutive six month period) were selected for the study. More than 2,100 patients were classified based on urine drug testing results. The study was funded by Ameritox.

    For the full text or a PDF of this study, please go to:

    http://www.ajmc.com/issue/managed-care/2011/2011-1-vol17-n1/AJMC_2011jan_Leider_32to40

    About Ameritox: Ameritox is the nation's leader in pain medication monitoring solutions, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provides physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers Rx Guardian(SM), the
    '/>"/>

    SOURCE Ameritox Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
    2. Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
    3. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
    4. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
    5. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
    6. BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
    7. Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
    8. DATATRAK Awarded First Study With Kreara Solutions
    9. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
    10. Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
    11. Educational Efforts Reduce COPD Costs by $3.4 Million in East Texas Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/31/2015)... 2015  SynCardia Systems, Inc. has received FDA approval ... on the effective use of its 50cc SynCardia temporary ... The FDA approval will allow SynCardia to ... failure patients. Patients enrolled in this study will receive ... to a donor heart transplant. (Caution-In the United ...
    (Date:3/31/2015)... March 31, 2015 MedSpring Urgent Care is pleased to ... Dallas/Fort-Worth area of Upper Greenville. The center – located ... Dallas location. Knox - Henderson ... the surrounding community since opening last fall. Additional Dallas ... Keller and Las Colinas neighborhoods this summer. ...
    (Date:3/31/2015)... AVIV, Israel, March 31, 2015  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, today announced ... 31, 2014. Fourth Quarter 2014 Highlights: ... featuring a keynote address by Professor Rohit Loomba, ...
    Breaking Medicine Technology:FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4MedSpring Urgent Care Opens New Upper Greenville Location in Dallas 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8
    ... ALBUQUERQUE, N.M., Sept. 2 Clinical Lab,Products ... BMOD),( http://www.biomoda.com ) and its proprietary early ... more promising advances in the cancer diagnostic,technology. ... makes particular,note of the assay,s simplicity that ...
    ... Invasive Surgery at St.,Luke,s-Roosevelt Hospital Center completes his ... benefiting from ,hidden scar, procedure, CUPERTINO, Calif., ... completion of a series of single port Lap-Band,procedures ... pain for,patients. Dr. Julio Teixeira at St. Luke,s-Roosevelt ...
    Cached Medicine Technology:Clinical Lab Products Magazine Features Biomoda 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 3
    (Date:3/31/2015)... 2015 When SIGVARIS launched the EVERSHEER compression ... product launch to date. Women immediately fell in love with ... another reason to love EVERSHEER with the launch of a ... , Lavender mist pairs perfectly with a variety of navy, ... women looking to add a hint of spring to their ...
    (Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By ... (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), ... and studies the major market drivers, restraints, opportunities ... the Rest of the world (RoW). , ... reach $3.58 billion by 2019 from $2.4 billion ...
    (Date:3/31/2015)... 31, 2015 Safeware has ... Employers in Central Ohio, an awards program presented by ... winners of the awards program, held on March 10, ... to employee health, with outstanding health and wellness initiatives. ... to creating a healthy environment for their associates. Business ...
    (Date:3/31/2015)... Spring Hill, FL (PRWEB) March 31, 2015 ... and Substance Abuse (CASA) at Columbia University states that ... arrested in the U.S. and enter state juvenile justice ... abuse problems, are under the influence of drugs or ... of these factors. Despite this high incidence of substance-related ...
    (Date:3/31/2015)... Italy (PRWEB) March 31, 2015 A' ... the design project Bruker EVOQ by Daniel Dion has ... Design Award in Scientific Instruments, Medical Devices and ... EVOQ, Daniel Dion, the creative mind behind the award ... EVOQ MS - developed under the direction of Dr. ...
    Breaking Medicine News(10 mins):Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:Safeware Recognized as a Healthiest Employer in Central Ohio 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 3Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 4Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2
    ... , RESTON, Va., Aug. 11 ... the digital world, today released a study of the online health ... online consumer activity. While the number of visitors to health insurance ... increase in the number of searches related to obtaining health coverage ...
    ... engineered white blood cells could include drug testing, researchers ... new technique that transforms embryonic and adult stem cells ... produce blood cells with specific defects for use by ... The method, devised by University of Wisconsin-Madison researchers, could ...
    ... study conducted at the Jefferson Headache Center at ... an investigational, orally-inhaled therapy is effective in treating ... for the orally-inhaled migraine therapy, LEVADEX, shows study ... pain, nausea and light and sound sensitivity when ...
    ... NewYork-Presbyterian Hospital/Weill Cornell Medical Center will create a New York ... treatment for elder abuse cases in the New York City ... focus on coordinating elder abuse cases, the Center has received ... Leslie R. Samuels Foundation and $75,250 from the FJC, A ...
    ... , WASHINGTON, Aug. 11 The Partnership to ... care provisions contained within health reform legislation passed out of committee. ... be improved to increase quality of care and reduce health care ... other legislation is introduced, specifically the Senate Finance Committee plan. , ...
    ... , , LAKE FOREST, Ill., Aug. ... leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug ... States. The medication is a generic version of Sanofi-Aventis, Eloxatin(R), which ... is one of the first generic versions of this drug to ...
    Cached Medicine News:Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 3Health News:Stem Cell Advance May Further Disease Research 2Health News:NYC's first elder abuse center created by NYP/Weill Cornell in collaboration with community partners 2Health News:NYC's first elder abuse center created by NYP/Weill Cornell in collaboration with community partners 3Health News:Partnership to Fight Chronic Disease Analyzes Key Provisions in Health Care Legislation Released To-Date 2Health News:Hospira Launches Generic Oxaliplatin Injection 2Health News:Hospira Launches Generic Oxaliplatin Injection 3
    Handheld Digital Retinal Camera...
    Inquire...
    Specifically for placing follicular units....
    ... are available in three styles ... available non-sterile and sterile, and ... Depending on the patient needs, ... or two implants (medial and ...
    Medicine Products: